Copyright: © 2020 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Patients and methods: We prepared CDDP/CQ-PLA NPs and CDDP-PLA NPs. Transmission electron microscopy (TEM) and dynamic light scattering (DLS) were used to detect the physiological characteristics and particle size parameters of drug-loaded nanoparticles. The drug concentration and cumulative release were measured by UV and visible spectrophotometer. MTT assay was used to detect viability of Cal-27 cells. Annexin/PI staining was used to detect cell apoptosis. Biological kits were used to detect malondialdehyde (MDA) content, catalase (CAT) activity, antioxidant enzyme superoxide dismutase (SOD) activity and glutathione peroxidase (GSH PX) activity in Cal-27 cells. Western blot was used to detect apoptosis and autophagy of Cal-27 cells.
Results: CDDP/CQ-PLA NPs and CDDP -PLA NPs had good drug loaded nanoparticles and drug release. CDDP/CQ-PLA NPs showed higher ROS and apoptosis rate, and lower autophagy than CDDP-PLA NPs.
Conclusion: CDDP/CQ-PLA NPs reduced autophagy and enhanced ROS and apoptosis of Cal-27 cells, which shows a potential in the clinical treatment of OSCC.